Back to company

LEO PHARMA A/S: Financial statements 2019

CVR: 56759514

LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 10,805,000,000 and a net result of DKK -1,287,000,000 compared with DKK 1,258,000,000 the year before. That is an increase of 3.8% compared with the year before. The profit margin was -11.9%. Equity amounted to DKK 8,088,000,000. The solvency ratio was 32.7%.

Revenue
10,805,000,000 kr.
Gross Profit
7,455,000,000 kr.
Profit/Loss
-1,287,000,000 kr.
Equity
8,088,000,000 kr.
Total Assets
24,760,000,000 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
201910.8 mia.7.5 mia.-1.3 mia.8.1 mia.-
201810.4 mia.7.4 mia.1.3 mia.9.5 mia.-
201710.5 mia.7.5 mia.1.4 mia.8.3 mia.-
20167.4 mia.2.7 mia.743 mio.25.2 mia.5170
20156.9 mia.2 mia.645 mio.25.3 mia.4813

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2019

Jane Maria Birgitta Stymne Göransson joins the board of LEO PHARMA A/SNov 13, 2019

As of November 13, 2019, Jane Maria Birgitta Stymne Göransson has joined the board of directors of LEO PHARMA A/S.

Catherine Thérése Jeanne Mazzacco joins LEO PHARMA A/S as adm. dir.Aug 1, 2019

As of August 1, 2019, Catherine Thérése Jeanne Mazzacco is registered as adm. dir. of LEO PHARMA A/S.

Gitte Pugholm Aabo steps down as adm. dir. of LEO PHARMA A/SJul 31, 2019

As of July 31, 2019, Gitte Pugholm Aabo has stepped down as adm. dir. of LEO PHARMA A/S.

LEO PHARMA A/S: The 2018 annual report is outMar 21, 2019

LEO PHARMA A/S has published its annual report for 2018. Revenue came to DKK 10,410,000,000, and the net result was DKK 1,258,000,000.

Anders Ekblom joins the board of LEO PHARMA A/SFeb 26, 2019

As of February 26, 2019, Anders Ekblom has joined the board of directors of LEO PHARMA A/S.

Olivier Bohuon joins the board of LEO PHARMA A/SFeb 26, 2019

As of February 26, 2019, Olivier Bohuon has joined the board of directors of LEO PHARMA A/S.

Jukka Pekka Pertola leaves the board of LEO PHARMA A/SFeb 26, 2019

As of February 26, 2019, Jukka Pekka Pertola has left the board of directors of LEO PHARMA A/S.

John Robert Weeks leaves the board of LEO PHARMA A/SFeb 26, 2019

As of February 26, 2019, John Robert Weeks has left the board of directors of LEO PHARMA A/S.

Laurids Bonne Bjørnshauge joins the board of LEO PHARMA A/SFeb 25, 2019

As of February 25, 2019, Laurids Bonne Bjørnshauge has joined the board of directors of LEO PHARMA A/S.

Irene Anett Jonassen leaves the board of LEO PHARMA A/SFeb 25, 2019

As of February 25, 2019, Irene Anett Jonassen has left the board of directors of LEO PHARMA A/S.

About LEO PHARMA A/S

LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Philip Harald Eickhoff and Christophe Dominique Luc Charles Bourdon. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 2,040 employees. In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity amounted to DKK 5,262,000,000.